| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Perspective Therapeutics, Inc. (CATX) has 8 insiders with recent SEC Form 4 filings, including 13 buys and 0 sells. CATX is classified in the Health Care Equipment & Supplies industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 735.0K | $2.21M | - | |
| CFO | 600.0K | $1.80M | - | |
| Other | 150.0K | $450.0K | - | |
| Other | 90.0K | $270.0K | - | |
| Dir | 75.0K | $225.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 22, 2020 | McCormick Michael W | Director | Buy | 19,230 | $0.52 | $9,999.60 | +87.4% | |
| Nov 20, 2019 | Krachon Michael | VP Of Sales &Marketing | Buy | 50,000 | $0.39 | $19,495.00 | New | |
| Nov 15, 2019 | Cavanagh William | Chief R&D Officer | Buy | 10,000 | $0.39 | $3,900.00 | +100.0% | |
| Nov 15, 2019 | Woods Lori A70 | CEO | Buy | 150,000 | $0.40 | $59,295.00 | +39.0% | |
| Nov 20, 2018 | Hoffmann Alan | Director | Buy | 25,000 | $0.40 | $10,000.00 | +125.0% | |
| Nov 16, 2018 | Austin Mark John | Controller/ Prin Fin&Acct Offic | Buy | 4,283 | $0.40 | $1,702.92 | +36.6% | |
| Nov 16, 2018 | Cavanagh William | COO, CSO | Buy | 10,000 | $0.40 | $4,000.00 | New | |
| Nov 15, 2018 | Woods Lori A70 | Interim CEO | Buy | 130,000 | $0.40 | $51,730.98 | +51.1% | |
| Nov 13, 2018 | Austin Mark John | Controller/ Prin Fin&Acct Offic | Buy | 2,452 | $0.41 | $1,005.32 | +26.5% | |
| Nov 13, 2018 | Vitale Philip J | Director | Buy | 30,000 | $0.43 | $12,900.00 | +37.5% |